Expression of high-molecular-weight cytokeratin (34βE12) is an independent predictor of disease-free survival in patients with triple-negative tumours of the breast

Rutika Mehta, Rohit K. Jain, Nour Sneige, Sunil Badve, Erika Resetkova

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

One-fifth of breast cancers have the triple-negative phenotype; a good prognostic marker has yet not been described for these tumours. Tumour microarrays from 58 triple-negative patients treated with surgery followed by chemotherapy were analysed for expression of cytokeratin 5/6 (CK5/6), epidermal growth factor receptor (EGFR), vimentin, p63 and cytokeratin 34βE12. The mean patient age was 59.2 years with a follow-up from 39 to 168 months. Clinicopathological variables and survival data were correlated with biomarker expression. The frequency of expression of cytokeratin 5/6, EGFR, vimentin, p63 and 34βE12 was 33%, 65%, 50%, 19% and 85%, respectively. Each of 34βE12, p63, EGFR and T stage significantly correlated with both disease-free survival and overall survival. T stage and 34βE12 were independent predictors of overall survival in a multivariate analysis. Expression of 34βE12 predicts disease-free and overall survival in patients with triple-negative tumours. Additional studies are planned to confirm these initial findings.

Original languageEnglish
Pages (from-to)744-747
Number of pages4
JournalJournal of Clinical Pathology
Volume63
Issue number8
DOIs
StatePublished - Aug 2010

Fingerprint

Keratins
Keratin-6
Epidermal Growth Factor Receptor
Keratin-5
Disease-Free Survival
Molecular Weight
Vimentin
Breast Neoplasms
Survival
Triple Negative Breast Neoplasms
Neoplasms
Multivariate Analysis
Biomarkers
Phenotype
Drug Therapy

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Expression of high-molecular-weight cytokeratin (34βE12) is an independent predictor of disease-free survival in patients with triple-negative tumours of the breast. / Mehta, Rutika; Jain, Rohit K.; Sneige, Nour; Badve, Sunil; Resetkova, Erika.

In: Journal of Clinical Pathology, Vol. 63, No. 8, 08.2010, p. 744-747.

Research output: Contribution to journalArticle

@article{b48479cdcbe34d97a862da36ede5b2e5,
title = "Expression of high-molecular-weight cytokeratin (34βE12) is an independent predictor of disease-free survival in patients with triple-negative tumours of the breast",
abstract = "One-fifth of breast cancers have the triple-negative phenotype; a good prognostic marker has yet not been described for these tumours. Tumour microarrays from 58 triple-negative patients treated with surgery followed by chemotherapy were analysed for expression of cytokeratin 5/6 (CK5/6), epidermal growth factor receptor (EGFR), vimentin, p63 and cytokeratin 34βE12. The mean patient age was 59.2 years with a follow-up from 39 to 168 months. Clinicopathological variables and survival data were correlated with biomarker expression. The frequency of expression of cytokeratin 5/6, EGFR, vimentin, p63 and 34βE12 was 33{\%}, 65{\%}, 50{\%}, 19{\%} and 85{\%}, respectively. Each of 34βE12, p63, EGFR and T stage significantly correlated with both disease-free survival and overall survival. T stage and 34βE12 were independent predictors of overall survival in a multivariate analysis. Expression of 34βE12 predicts disease-free and overall survival in patients with triple-negative tumours. Additional studies are planned to confirm these initial findings.",
author = "Rutika Mehta and Jain, {Rohit K.} and Nour Sneige and Sunil Badve and Erika Resetkova",
year = "2010",
month = "8",
doi = "10.1136/jcp.2010.076653",
language = "English",
volume = "63",
pages = "744--747",
journal = "Journal of Clinical Pathology - Clinical Molecular Pathology",
issn = "0021-9746",
publisher = "BMJ Publishing Group",
number = "8",

}

TY - JOUR

T1 - Expression of high-molecular-weight cytokeratin (34βE12) is an independent predictor of disease-free survival in patients with triple-negative tumours of the breast

AU - Mehta, Rutika

AU - Jain, Rohit K.

AU - Sneige, Nour

AU - Badve, Sunil

AU - Resetkova, Erika

PY - 2010/8

Y1 - 2010/8

N2 - One-fifth of breast cancers have the triple-negative phenotype; a good prognostic marker has yet not been described for these tumours. Tumour microarrays from 58 triple-negative patients treated with surgery followed by chemotherapy were analysed for expression of cytokeratin 5/6 (CK5/6), epidermal growth factor receptor (EGFR), vimentin, p63 and cytokeratin 34βE12. The mean patient age was 59.2 years with a follow-up from 39 to 168 months. Clinicopathological variables and survival data were correlated with biomarker expression. The frequency of expression of cytokeratin 5/6, EGFR, vimentin, p63 and 34βE12 was 33%, 65%, 50%, 19% and 85%, respectively. Each of 34βE12, p63, EGFR and T stage significantly correlated with both disease-free survival and overall survival. T stage and 34βE12 were independent predictors of overall survival in a multivariate analysis. Expression of 34βE12 predicts disease-free and overall survival in patients with triple-negative tumours. Additional studies are planned to confirm these initial findings.

AB - One-fifth of breast cancers have the triple-negative phenotype; a good prognostic marker has yet not been described for these tumours. Tumour microarrays from 58 triple-negative patients treated with surgery followed by chemotherapy were analysed for expression of cytokeratin 5/6 (CK5/6), epidermal growth factor receptor (EGFR), vimentin, p63 and cytokeratin 34βE12. The mean patient age was 59.2 years with a follow-up from 39 to 168 months. Clinicopathological variables and survival data were correlated with biomarker expression. The frequency of expression of cytokeratin 5/6, EGFR, vimentin, p63 and 34βE12 was 33%, 65%, 50%, 19% and 85%, respectively. Each of 34βE12, p63, EGFR and T stage significantly correlated with both disease-free survival and overall survival. T stage and 34βE12 were independent predictors of overall survival in a multivariate analysis. Expression of 34βE12 predicts disease-free and overall survival in patients with triple-negative tumours. Additional studies are planned to confirm these initial findings.

UR - http://www.scopus.com/inward/record.url?scp=77955754574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955754574&partnerID=8YFLogxK

U2 - 10.1136/jcp.2010.076653

DO - 10.1136/jcp.2010.076653

M3 - Article

C2 - 20702478

AN - SCOPUS:77955754574

VL - 63

SP - 744

EP - 747

JO - Journal of Clinical Pathology - Clinical Molecular Pathology

JF - Journal of Clinical Pathology - Clinical Molecular Pathology

SN - 0021-9746

IS - 8

ER -